X0306
4
2013-09-11
1
0001356857
Trius Therapeutics Inc
TSRX
0001231845
EASTHAM KARIN
C/O TRIUS THERAPEUTICS, INC.
6310 NANCY RIDGE DR, # 105
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2013-09-11
4
D
0
6000
D
0
D
Common Stock
2013-09-11
4
D
0
12114
D
0
I
Karin Eastham Defined Benefit Plan
Stock Option (right to buy)
7.57
2013-09-11
4
D
0
17441
5.93
D
2019-11-03
Common Stock
17441
0
D
Stock Option (right to buy)
3.50
2013-09-11
4
D
0
6000
10.00
D
2020-11-02
Common Stock
6000
0
D
Stock Option (right to buy)
8.26
2013-09-11
4
D
0
12000
5.24
D
2021-06-01
Common Stock
12000
0
D
Stock Option (right to buy)
5.05
2013-09-11
4
D
0
12000
8.45
D
2022-05-21
Common Stock
12000
0
D
Stock Option (right to buy)
7.77
2013-09-11
4
D
0
15000
5.73
D
2023-05-20
Common Stock
15000
0
D
Pursuant the terms of that certain Agreement and Plan of Merger, dated as of July 30, 2013, by and among Trius Therapeutics, Inc., Cubist Pharmaceuticals, Inc., and BRGO Corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Trius common stock was validly tendered for $13.50 per share in cash plus one non-transferrable contingent value right for each share (each a "CVR"), which represents the contractual right to receive up to $2.00 per share upon the achievement of certain milestones, subject to any required withholding of taxes.
Pursuant the terms of the Merger Agreement and the Offer, each stock option that was outstanding and unexercised as of the Offer Acceptance Time (as defined in the Merger Agreement), whether or not vested, was cancelled and converted into the right to receive $13.50 per share (minus the exercise price of the option) in cash plus one CVR which represents the contractual right to receive up to $2.00 per share upon the achievement of certain milestones, subject to any required withholding of taxes.
/s/ Michael Morneau, Attorney-in-Fact
2013-09-12